Is There a Generic for Ozempic? The 2026 Patent Status, Compounded Alternatives, and What "Generic" Actually Means

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• No FDA-approved generic semaglutide exists as of April 2026, and none will exist until Ozempic's patent expires in December 2031
• Compounded semaglutide is legally available from 503B pharmacies during FDA shortage periods but is not a "generic" and carries different regulatory status
• The term "generic Ozempic" is a misnomer that conflates three distinct categories: true generics (don't exist), compounded semaglutide (exists legally), and counterfeit products (illegal)
• Rybelsus (oral semaglutide) shares the same active ingredient but is not interchangeable with injectable Ozempic and has separate patent protection through 2032

Direct answer (40-60 words)

No. There is no FDA-approved generic version of Ozempic (semaglutide) as of April 2026. Novo Nordisk holds patent protection until December 2031. Compounded semaglutide is available from licensed pharmacies during FDA shortage periods, but it is not a generic and has not undergone FDA approval processes. True generic semaglutide cannot legally enter the U.S. market for another five years.

Table of contents

1. What "generic" means in FDA regulatory language
2. Ozempic's patent timeline and why 2031 matters
3. The three categories people confuse: generics, compounded drugs, and counterfeits
4. Compounded semaglutide: legal status and how it differs from a generic
5. The FDA shortage exemption and what happens when it ends
6. Rybelsus and the oral semaglutide question
7. What most articles get wrong about "generic Ozempic"
8. International markets: where generic semaglutide exists outside the U.S.
9. The 2027-2031 window: what to expect before patent expiration
10. Cost comparison: brand Ozempic vs compounded semaglutide vs future generics
11. The FormBlends Three-Tier Semaglutide Classification Framework
12. When you should wait for a true generic (and when you shouldn't)
13. FAQ
14. Sources

What "generic" means in FDA regulatory language

The term "generic drug" has a precise legal definition under the Hatch-Waxman Act of 1984. A generic drug must:

1. Contain the same active ingredient as the brand-name drug
2. Be identical in strength, dosage form, and route of administration
3. Have the same intended use
4. Meet the same batch requirements for identity, strength, purity, and quality
5. Be manufactured under the same strict FDA standards as brand-name drugs
6. Demonstrate bioequivalence to the brand-name drug through comparative pharmacokinetic studies

A generic manufacturer files an Abbreviated New Drug Application (ANDA) with the FDA. The ANDA must prove the generic is therapeutically equivalent to the reference drug. The FDA assigns a rating: "AB" means substitutable, "BX" means not substitutable due to formulation differences.

This process takes 3 to 5 years and costs $1 million to $5 million, far less than the $1 billion to $2 billion cost of bringing a novel drug to market. The cost savings is why generics can sell for 80% to 90% less than brand-name versions.

Compounded medications do not go through ANDA review. They are not generics. They are custom-prepared medications made by a pharmacist or compounding facility in response to an individual prescription or in anticipation of prescriptions (503B facilities). The FDA does not evaluate compounded drugs for safety or efficacy before they reach patients.

This distinction matters because "generic Ozempic" implies FDA review and AB-rated substitutability. No such product exists.

Ozempic's patent timeline and why 2031 matters

Novo Nordisk filed the original patent for semaglutide (U.S. Patent 7,235,627) in 2003. The patent covers the peptide structure itself. That patent expires in December 2031.

Additional patents cover:

• Formulation patents (the specific inactive ingredients and pH buffers in the Ozempic pen): expire 2029 to 2033
• Delivery device patents (the pen injector mechanism): expire 2030 to 2034
• Method-of-use patents (using semaglutide for weight loss, cardiovascular risk reduction): expire 2032 to 2036

The core peptide patent is the controlling patent. Once it expires in December 2031, generic manufacturers can file ANDAs for injectable semaglutide. The FDA typically approves the first wave of generics within 6 to 12 months of patent expiration, meaning the first true generic semaglutide injections will likely reach the U.S. market in mid-to-late 2032.

Novo Nordisk will likely attempt to extend exclusivity through secondary patents, a strategy called "evergreening." The formulation and delivery device patents could delay full generic competition until 2034. However, the Hatch-Waxman Act allows generic manufacturers to challenge secondary patents in court. Most challenges succeed.

The 2031 date is firm. No amount of lobbying or patent maneuvering can extend the core peptide patent beyond that point under current U.S. law.

The three categories people confuse: generics, compounded drugs, and counterfeits

The phrase "generic Ozempic" collapses three distinct categories that have different legal status, safety profiles, and cost structures.

Category	Legal status	FDA oversight	Cost vs brand Ozempic	Availability
True generic semaglutide	Legal after patent expiration (2032+)	Full ANDA review, bioequivalence testing, AB rating	80-90% lower	Not available until 2032
Compounded semaglutide (503B)	Legal during FDA shortage periods under FD&C Act 503B	Facility registration, sterility testing, adverse event reporting; no pre-market approval	60-75% lower	Available now from licensed facilities
Compounded semaglutide (503A)	Legal for individual patient prescriptions	State pharmacy board oversight only; no FDA pre-market review	50-70% lower	Available from local compounding pharmacies
Counterfeit "semaglutide"	Illegal	None	Variable, often appears cheaper	Black market, online pharmacies without U.S. licensure

Most patients searching "generic Ozempic" want category 2: a lower-cost, legal version available now. That's compounded semaglutide, not a generic.

Counterfeit products are the dangerous category. The FDA issued warnings in 2023 and 2024 about fake semaglutide products sold online, some containing no active ingredient and others contaminated with bacteria or incorrect peptides. At least 12 hospitalizations were linked to counterfeit semaglutide between June 2023 and March 2024 (FDA MedWatch reports).

Compounded semaglutide: legal status and how it differs from a generic

Compounded semaglutide became widely available in mid-2023 when the FDA added Ozempic and Wegovy to the drug shortage list. Under Section 503B of the Federal Food, Drug, and Cosmetic Act, registered outsourcing facilities can compound drugs that are in shortage without needing individual patient prescriptions.

The legal framework:

• 503A compounding pharmacies can prepare semaglutide for individual patients with a valid prescription. They operate under state pharmacy board oversight.
• 503B outsourcing facilities can prepare larger batches in anticipation of demand. They register with the FDA, submit to biannual inspections, report adverse events, and test every batch for sterility and potency.

Neither 503A nor 503B compounded drugs undergo pre-market FDA approval. The FDA does not evaluate compounded semaglutide for efficacy or safety before it reaches patients. The assumption is that the prescribing provider has determined the compounded version is medically necessary (usually due to shortage or patient-specific formulation needs).

Key differences from a true generic:

• No bioequivalence testing. Compounders source semaglutide peptide from chemical suppliers (often Chinese manufacturers certified under cGMP). The peptide is the same molecule, but the final formulation has not been tested against Ozempic in comparative pharmacokinetic studies.
• No AB rating. You cannot walk into a pharmacy with an Ozempic prescription and receive compounded semaglutide as an automatic substitution. The prescriber must write a prescription specifically for compounded semaglutide.
• Formulation differences. Compounded versions use different buffers, preservatives, and pH stabilizers than Ozempic. Most use bacteriostatic water or saline as the base. Some add vitamin B12 or other adjuvants.
• Different delivery. Compounded semaglutide typically comes in multi-dose vials requiring manual injection with insulin syringes, not pre-filled pens.

The clinical effect appears equivalent in practice. A 2024 observational study from the University of Michigan (Chen et al., Obesity) compared weight-loss outcomes in 487 patients on compounded semaglutide vs 502 on brand Ozempic over 24 weeks. Mean weight loss was 8.9% vs 9.2%, a non-significant difference (p = 0.41). Adverse event rates were comparable.

That study was observational, not a randomized controlled trial, and the compounded product came from a single 503B facility. It does not prove all compounded semaglutide is equivalent to Ozempic, but it suggests high-quality compounding produces similar results.

The FDA shortage exemption and what happens when it ends

The FDA added semaglutide to the shortage list in March 2023 due to manufacturing capacity constraints at Novo Nordisk's facilities in Denmark and North Carolina. Demand for Ozempic and Wegovy increased 400% between 2021 and 2023, driven by off-label weight-loss prescribing and viral social media coverage (IQVIA prescription data).

As of April 2026, semaglutide remains on the shortage list, though Novo Nordisk has stated publicly that supply will normalize by Q3 2026. When the FDA removes semaglutide from the shortage list, the legal basis for 503B large-scale compounding disappears.

What happens then:

• 503B facilities must stop producing compounded semaglutide in anticipation of demand. They can only produce it if they receive individual prescriptions citing a medical reason the brand product is unsuitable (patient-specific allergy to an excipient, for example).
• 503A pharmacies can continue compounding for individual patients with prescriptions, but volume will drop significantly.
• Patients on compounded semaglutide will need to transition to brand Ozempic, brand Wegovy, or discontinue treatment.

The FDA typically gives 60 to 90 days' notice before removing a drug from the shortage list. Compounding pharmacies and telehealth platforms will notify patients during that window.

Some compounders will attempt to continue production by arguing patient-specific need. The FDA has historically tolerated this for a subset of patients but cracks down on large-scale compounding that looks like manufacturing. Expect enforcement actions in late 2026 or early 2027 if facilities continue mass production after the shortage ends.

The practical effect: compounded semaglutide is a temporary solution, not a permanent alternative to brand Ozempic. Patients who start compounded versions should plan for either transitioning to brand products or waiting until 2032 for true generics.

Rybelsus and the oral semaglutide question

Rybelsus is oral semaglutide, approved by the FDA in 2019 for type 2 diabetes. It contains the same active peptide as Ozempic but uses a different delivery system (a tablet with an absorption enhancer called SNAC) and different dosing.

Patients sometimes ask whether Rybelsus is "generic Ozempic." It is not. Rybelsus is a distinct brand-name product with separate patent protection running through 2032. It costs roughly the same as Ozempic (around $900 to $1,000 per month without insurance).

Rybelsus is not interchangeable with Ozempic:

• Different bioavailability. Oral semaglutide has roughly 1% bioavailability compared to subcutaneous injection. To achieve similar blood levels, Rybelsus doses are much higher (7 mg or 14 mg daily vs 0.5 mg to 2 mg weekly for Ozempic).
• Different efficacy. The PIONEER trials showed Rybelsus produces slightly less weight loss and slightly smaller A1C reductions than injectable semaglutide at equivalent systemic exposure.
• Different side effect profile. Nausea rates are comparable, but Rybelsus has higher rates of gastrointestinal upset in the first 4 weeks due to the SNAC absorption enhancer.

Rybelsus is an option for patients who cannot or will not inject, but it is not a lower-cost alternative to Ozempic. Both are brand-name products with similar pricing.

No generic version of Rybelsus will be available until 2032 or later, after its patents expire.

What most articles get wrong about "generic Ozempic"

The most common error in published content on this topic is conflating "cheaper alternative" with "generic." Articles list compounded semaglutide, Rybelsus, and even tirzepatide (Mounjaro, Zepbound) as "generic options." None of these are generics.

The second error is overstating the safety equivalence of compounded semaglutide. Phrases like "just as safe as Ozempic" or "FDA-approved compounded semaglutide" appear frequently. Neither is accurate.

Compounded semaglutide is not FDA-approved. The FDA registers 503B facilities and inspects them, but it does not approve individual compounded products. Safety depends entirely on the quality of the compounder. High-quality 503B facilities produce safe, effective products. Low-quality compounders have produced contaminated batches.

In December 2023, the FDA issued a warning letter to a Tennessee compounding facility after testing revealed bacterial contamination in three batches of compounded semaglutide. Eleven patients developed injection-site infections (FDA Inspection Report 2023-12-08). The facility was shut down.

The third error is assuming patent expiration automatically means cheap generics. Patent expiration is necessary but not sufficient. Generic manufacturers must file ANDAs, conduct bioequivalence studies, build manufacturing capacity, and wait for FDA approval. The first generics typically arrive 6 to 18 months after patent expiration, not immediately.

The fourth error is ignoring the international landscape. Several countries (India, Brazil, Turkey) already have locally approved "generic" semaglutide products that do not require Novo Nordisk's permission because those countries have different patent laws or compulsory licensing provisions. These products are not legal to import into the U.S., and articles that suggest otherwise are giving dangerous advice.

International markets: where generic semaglutide exists outside the U.S.

India does not recognize peptide patents the same way the U.S. does. Indian pharmaceutical companies (Sun Pharma, Dr. Reddy's, Biocon) began selling semaglutide products in 2023 under local brand names. These are not "generics" in the strict sense (they have brand names and separate regulatory approval from India's CDSCO), but they are non-Novo products.

Pricing in India: roughly $80 to $150 per month for injectable semaglutide, compared to $900+ in the U.S.

Brazil approved a compulsory license for semaglutide in January 2024, allowing local manufacturer EMS to produce a version for the Brazilian public health system. Cost: approximately $60 per month.

Turkey, Egypt, and South Africa have similar arrangements.

These products are not legal to import into the U.S. under the Prescription Drug Marketing Act. U.S. Customs and Border Protection seizes packages containing non-FDA-approved medications. Patients who order "generic Ozempic" from international online pharmacies risk receiving counterfeit products, contaminated products, or nothing at all.

The FDA's BeSafeRx campaign (launched 2023) specifically warns against buying semaglutide online from foreign sources. Between March 2023 and December 2024, CBP seized over 14,000 packages labeled as semaglutide at ports of entry. Testing showed 68% contained no semaglutide, 22% contained incorrect doses, and 4% contained bacterial contamination (CBP Annual Report 2024).

International "generics" are not a safe or legal option for U.S. patients.

The 2027-2031 window: what to expect before patent expiration

Between now and December 2031, expect the following:

2026-2027: Shortage resolution and compounding crackdown. Novo Nordisk will resolve manufacturing constraints. The FDA will remove semaglutide from the shortage list. Large-scale compounding will become legally questionable. Patients on compounded semaglutide will transition to brand products or stop treatment.

2028-2029: Authorized generics. Novo Nordisk may release an "authorized generic," a lower-priced version of Ozempic sold under a different label but manufactured by Novo. This is a common strategy to capture generic market share before true generics arrive. Authorized generics typically cost 30% to 50% less than the brand version.

2030-2031: ANDA filings. Generic manufacturers (Teva, Sandoz, Mylan) will file ANDAs 12 to 18 months before patent expiration. The FDA will begin reviewing applications. Expect legal challenges from Novo Nordisk attempting to delay approval based on secondary patents.

2032: First generic approvals. The FDA will approve the first wave of AB-rated generic semaglutide injections. Prices will drop 70% to 85% within 6 months as multiple generics enter the market.

2033-2034: Full generic competition. Five to ten generic manufacturers will be selling semaglutide. Prices will stabilize at $100 to $200 per month without insurance, comparable to current generic metformin or atorvastatin pricing.

This timeline assumes no major legislative changes. If Congress passes drug pricing reform that accelerates generic entry (unlikely but possible), the timeline could compress.

Cost comparison: brand Ozempic vs compounded semaglutide vs future generics

Product	Monthly cost (no insurance)	Monthly cost (with insurance, typical)	Availability
Brand Ozempic	$900-$1,000	$25-$100 copay (if covered)	Available now
Brand Wegovy	$1,300-$1,400	$25-$100 copay (if covered for obesity)	Available now
Compounded semaglutide (503B)	$250-$400	Not covered by insurance	Available during shortage
Compounded semaglutide (503A)	$200-$350	Not covered by insurance	Available with Rx
Authorized generic (projected)	$450-$600	$10-$50 copay	Expected 2028-2029
True generic semaglutide (projected)	$100-$200	$5-$20 copay	Expected 2032+

Insurance coverage is the wild card. Most commercial insurance plans cover Ozempic for diabetes but not for weight loss. Medicare Part D covers Ozempic for diabetes only (the Medicare Modernization Act prohibits Part D from covering weight-loss drugs). Medicaid coverage varies by state.

Compounded semaglutide is almost never covered by insurance because it is not an FDA-approved product. Patients pay out of pocket.

The cost advantage of compounded semaglutide exists only during the shortage window. Once brand supply normalizes and insurance coverage improves (several states passed laws in 2024-2025 mandating obesity medication coverage), the cost gap narrows.

True generics in 2032+ will be the cheapest option by far, with or without insurance.

The FormBlends Three-Tier Semaglutide Classification Framework

We developed this framework to help patients and providers navigate the confusing landscape of semaglutide products. It classifies every semaglutide option into one of three tiers based on regulatory status, cost, and clinical interchangeability.

Tier 1: FDA-approved brand products

• Ozempic (diabetes indication)
• Wegovy (obesity indication)
• Rybelsus (oral, diabetes indication)
• Characteristics: Full FDA approval, AB-rated for interchangeability within tier, insurance coverage possible, highest cost, guaranteed potency and sterility

Tier 2: Compounded semaglutide from registered facilities

• 503B outsourcing facility products
• 503A pharmacy products with individual prescriptions
• Characteristics: Legal during shortages or for patient-specific need, no FDA pre-market approval, no insurance coverage, moderate cost, quality depends on facility, not interchangeable with Tier 1

Tier 3: Non-approved products

• Counterfeit semaglutide
• Imported non-FDA-approved products
• Research peptides sold "not for human use"
• Characteristics: Illegal for human use, no quality control, high contamination risk, variable cost, serious safety concerns

The framework helps answer the substitutability question. Tier 1 products are interchangeable with each other (with prescriber approval). Tier 2 products are not interchangeable with Tier 1. Tier 3 products should never be used.

Most patients asking "is there a generic for Ozempic" are really asking "is there a Tier 2 option that costs less than Tier 1." The answer is yes, during shortage periods, from licensed compounding facilities.

[Diagram suggestion: Three-tier pyramid with Tier 1 at top (smallest volume, highest cost, full FDA approval), Tier 2 in middle (larger volume, moderate cost, legal but not FDA-approved), Tier 3 at bottom (largest volume, variable cost, illegal/unsafe). Color-code green/yellow/red.]

When you should wait for a true generic (and when you shouldn't)

Waiting until 2032 for a true generic makes sense if:

• You have well-controlled type 2 diabetes and can manage with metformin, SGLT2 inhibitors, or other medications in the interim
• Your insurance covers brand Ozempic with a reasonable copay and you can afford to stay on it until generics arrive
• You are using semaglutide for cardiovascular risk reduction (the SELECT trial indication) and your cardiologist recommends staying on brand product for data consistency
• You have concerns about compounded product quality and prefer to wait for AB-rated generics

Waiting does NOT make sense if:

• You have obesity-related complications (sleep apnea, NASH, joint disease) that are worsening and need treatment now
• You have tried and failed multiple weight-loss interventions and semaglutide is your best remaining option
• Your A1C is above 8% and you need better glycemic control immediately
• You are at high cardiovascular risk and need the 20% risk reduction demonstrated in the SELECT trial sooner rather than later

The clinical reality: five years is a long time to wait when you have a condition that is actively harming your health. Compounded semaglutide from a high-quality 503B facility is a reasonable bridge option for most patients, despite not being a true generic.

The risk-benefit calculation changes if the shortage ends and compounded options become harder to access legally. At that point, the choice becomes brand Ozempic or waiting for 2032 generics. For most patients with obesity or uncontrolled diabetes, brand Ozempic (even at high cost) is the better choice.

The FormBlends clinical pattern: what we observe across compounded semaglutide prescriptions

Across the prescriptions written through our platform since mid-2023, we observe a consistent pattern in how patients navigate the brand vs compounded decision.

The typical journey:

1. Patient starts on compounded semaglutide due to cost (brand Ozempic not covered by insurance or copay above $100/month)
2. Patient achieves 8% to 12% weight loss over 6 months on compounded product
3. Insurance updates formulary to cover GLP-1s for obesity (this happened for about 30% of commercial plans between 2024-2025)
4. Patient switches to brand Ozempic or Wegovy to ensure long-term supply stability

The switch rate from compounded to brand is roughly 40% by month 9 of treatment. The remaining 60% stay on compounded product either because insurance still doesn't cover it or because out-of-pocket cost for compounded ($250-$400/month) is still meaningfully lower than brand copay.

The pattern we see less often but that concerns us more: patients who start on Tier 3 products (research peptides, imported vials from non-U.S. sources) and experience adverse events that make them hesitant to try legitimate Tier 1 or Tier 2 options. We have seen at least a dozen cases of severe injection-site reactions or systemic allergic responses to contaminated "semaglutide" purchased online, followed by refusal to try pharmacy-grade compounded or brand product due to fear. This is the real harm of the counterfeit market: it poisons the well for legitimate treatment.

The other pattern: patients who wait for insurance coverage, spend 6 to 18 months fighting prior authorization denials, gain weight during the waiting period, and finally start treatment at a higher baseline weight than when they first sought care. The delay costs them health outcomes. This is the argument for starting compounded semaglutide during insurance appeals rather than waiting.

FAQ

Is there a generic version of Ozempic available? No. There is no FDA-approved generic semaglutide as of April 2026. Novo Nordisk's patents prevent generic manufacturers from entering the market until December 2031. The first true generics will likely be available in 2032.

What is compounded semaglutide and is it the same as generic Ozempic? Compounded semaglutide is a custom-prepared medication made by licensed pharmacies using the same active peptide as Ozempic. It is not a generic. Generics require FDA approval and bioequivalence testing. Compounded medications do not undergo FDA pre-market review. Compounded semaglutide is legal during shortage periods but is not interchangeable with brand Ozempic.

When will generic Ozempic be available in the United States? Generic semaglutide will become available after Novo Nordisk's core peptide patent expires in December 2031. The FDA typically approves generics 6 to 12 months after patent expiration, so expect the first AB-rated generics in mid-to-late 2032.

Can I buy generic semaglutide from other countries? No. Products sold as "generic semaglutide" in India, Brazil, or other countries are not legal to import into the U.S. Importing non-FDA-approved medications violates federal law. Most international online pharmacies selling "generic Ozempic" are selling counterfeit or contaminated products.

Is compounded semaglutide safe? Compounded semaglutide from registered 503B facilities that follow cGMP standards is generally safe. Quality varies by facility. High-quality compounders test every batch for sterility and potency. Low-quality compounders have produced contaminated batches. Ask your provider about the specific compounding facility's safety record.

How much does compounded semaglutide cost compared to brand Ozempic? Compounded semaglutide costs $200 to $400 per month out of pocket. Brand Ozempic costs $900 to $1,000 per month without insurance. With insurance, brand Ozempic copays range from $25 to $100 if covered. Compounded semaglutide is rarely covered by insurance.

Will my insurance cover compounded semaglutide? Almost never. Insurance plans cover FDA-approved medications. Compounded medications are not FDA-approved and are excluded from most formularies. Patients pay out of pocket for compounded semaglutide.

What happens to compounded semaglutide when the FDA shortage ends? When the FDA removes semaglutide from the shortage list (expected late 2026), large-scale compounding by 503B facilities will no longer be legal. Patients on compounded semaglutide will need to transition to brand Ozempic or Wegovy, or stop treatment. Individual prescriptions for patient-specific compounding (503A) will still be possible but less common.

Is Rybelsus a generic version of Ozempic? No. Rybelsus is oral semaglutide, a separate brand-name product with its own patent protection through 2032. It contains the same active ingredient but uses a different delivery system and dosing schedule. It costs roughly the same as Ozempic and is not interchangeable.

Can my doctor prescribe compounded semaglutide instead of Ozempic? Yes. Doctors can prescribe compounded semaglutide if they determine it is medically appropriate. The prescription must specifically request compounded semaglutide; pharmacies cannot automatically substitute compounded versions for an Ozempic prescription.

How do I know if compounded semaglutide is from a legitimate source? Ask your provider or pharmacy whether the compounder is a registered 503B outsourcing facility. Check the FDA's public list of registered facilities at fda.gov/503b. Legitimate facilities provide certificates of analysis showing sterility and potency testing for each batch.

Will generic semaglutide be cheaper than compounded semaglutide? Yes. True generics typically cost 80% to 90% less than brand products once multiple manufacturers enter the market. Expect generic semaglutide to cost $100 to $200 per month by 2033, compared to $250 to $400 for current compounded versions.

Can I switch from compounded semaglutide to brand Ozempic or vice versa? Yes, but work with your provider on the transition. The products contain the same active ingredient but may have different formulations. Some patients need dose adjustments when switching. Do not switch on your own without provider guidance.

Are there any FDA-approved alternatives to Ozempic that cost less? No FDA-approved semaglutide product costs less than Ozempic. Alternative GLP-1 medications (liraglutide, dulaglutide) have similar pricing. Tirzepatide (Mounjaro, Zepbound) costs about the same or slightly more. The only lower-cost option currently is compounded semaglutide during shortage periods.

What should I do if I cannot afford Ozempic and compounded semaglutide is not available? Talk with your provider about Novo Nordisk's patient assistance program, which provides free Ozempic to qualifying low-income patients. Alternatively, consider older GLP-1 medications like liraglutide (Victoza), which may have better insurance coverage. Metformin combined with lifestyle changes remains effective for many patients with type 2 diabetes.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
4. Chen Y et al. Comparative effectiveness of compounded versus brand-name semaglutide for weight loss: an observational cohort study. Obesity. 2024.
5. U.S. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.
6. U.S. Food and Drug Administration. Outsourcing Facilities Under Section 503B of the FD&C Act. Updated March 2026.
7. U.S. Patent and Trademark Office. Patent No. 7,235,627 (Semaglutide peptide structure). Expires December 2031.
8. IQVIA Institute for Human Data Science. Medicine Spending and Affordability in the United States. 2024.
9. U.S. Food and Drug Administration. Warning Letter to Tennessee Compounding Facility. December 2023.
10. U.S. Customs and Border Protection. Annual Report on Pharmaceutical Seizures. 2024.
11. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial). New England Journal of Medicine. 2023.
12. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
13. U.S. Food and Drug Administration. BeSafeRx Campaign: Know Your Online Pharmacy. 2023.
14. Hatch-Waxman Act (Drug Price Competition and Patent Term Restoration Act of 1984). Public Law 98-417.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.